Pfizer Inc.
PFE (NYSE)
With a strong dividend yield of 7.01%, this investment offers attractive income potential, despite a challenging 5-year return of -39.96%. The 1-year return of 11.61% indicates recent recovery, bolstered by analyst ratings of "Buy" and "Outperform" from major firms, supporting a median 12-month price target of $27.50. Investors should weigh the high yield against past performance and consider the optimistic analyst outlook.
Pros:
- Strong dividend yield
- Recent positive returns
Cons:
- Significant negative 5-year return
- Market volatility risk
Pfizer Inc. (PFE) may be suitable for income-focused investors seeking a high dividend yield, particularly those willing to accept potential volatility given its significant decline over the past five years. While recent performance shows signs of recovery, prospective investors should carefully evaluate their risk tolerance and investment goals in light of both the company’s historical performance and current analyst sentiment.